DYN
Dyne TherapeuticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
+
Peers tracked
10
U.S. public peers
Grade Position
Below peers
vs peer average
DYN vs peer average
18/100
DYN vs. peer average (F vs. C)
Grade spread
A 1 · B 3 · C 1 · D 3 · F 1
Graded peers loaded
Coverage
10 graded
100% of tracked
Peer overview
NTLA is the first available peer comparator.
Intellia Therapeutics: in vivo gene-editing and delivery challenges mirror Dyne’s modality risks; useful for safety/delivery benchmarks [company PR].
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
DYN
Dyne Therapeutics
NTLA
Intellia Therapeutics
Grade
F
D
Momentum
52
17
Value
41
41
Sentiment
0
65
Setup Bias
Net Bullish
-
Market Cap
-
-
Posture
Defensive
Defensive
Grade position vs NTLA
DYN / NTLA
Grade Position
Below peers
DYN vs. peer average (F vs. C)
18/100
Momentum
52
DYNValue
41
DYNSentiment
0
NTLARotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs DYN
NTLA is the first peer returned for this comparison set.